Search Results - "Klitochenko, T."

BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A REAL WORLD SETTING: CLINICAL OUTCOMES AND IMPACT ON QUALITY OF LIFE by Ionova, T., Andrievskikh, M., Amdiev, A., Baryakh, E., Chang, V., Endakova, A., Fadeeva, N., Husainova, G., Ivanov, V., Kaplanov, K., Kaverina, O., Kiseleva, M., Klitochenko, T., Kurakin, V., Larionova, O., Lazareva, D., Lepik, K., Lysenko, I., Melnichenko, V., Mikhailova, N., Minullina, R., Mironov, O., Misyurina, E., Mochkin, N., Nikitina, T., Osipov, Y., Petrova, T., Porfirieva, N., Rukavitsyn, O., Safin, R., Samoylova, A., Shelekhova, T., Sherstnev, D., Simashova, P., Smirnova, E., Trenina, N., Vasiliev, E., Volodicheva, E.

Get full text

Combination of idarubicin, vinblastine, dacarbazine, and gemcitabine (IVDG) as therapy for elderly patients with Hodgkin lymphoma with cardiac and pulmonary comorbidity by Kaplanov, K., Klitochenko, T., Shipaeva, A., Shirokova, M., Matveeva, I., Lavrishina, N.

Get full text

P1724: QUALITY OF LIFE AND UNMET NEEDS AMONG PH‐NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS: RESULTS OF THE NATIONWIDE SURVEY by Ionova, T., Andreevskaya, E., Babich, E., Bulieva, N., Vinogradova, O., Volodicheva, E., Voloshin, S., Glonina, N., Dubov, S., Esefieva, N., Zinina, E., Ivanova, M., Klitochenko, T., Kopylova, A., Kulagin, A., Kuchma, G., Li, O., Lomaia, E., Melikyan, A., Melnichenko, V., Menshakova, S., Mitina, T., Morozova, E., Osipova, E., Ochirova, O., Polyakov, A., Pospelova, T., Proydakov, A., Rukavitsyn, O., Safuanova, G., Subortseva, I., Fominykh, M., Frolova, M., Shelekhova, T., Sherstnev, D., Shneyder, T., Shuvaev, V., Laane, E., Oliva, E., Salek, S., Nikitina, T.

Get full text

Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting by Pyadushkina, E. A., Derkach, E. V., Ignatyeva, V. I., Yagnenkova, E. E., Klitochenko, T. Yu, Shelekhova, T. V., Levanov, A. N.

“…Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma…”
Get full text

Combination of idarubicin, vinblastine, dacarbazine, and gemcitabine ( IVDG ) as therapy for elderly patients with H odgkin lymphoma with cardiac and pulmonary comorbidity by Kaplanov, K., Klitochenko, T., Shipaeva, A., Shirokova, M., Matveeva, I., Lavrishina, N.

Get full text

PS1158 IBRUTINIB PLUS RITUXIMUB IN STEROID REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA: ELABORATION OF TREATMENT APPROACH (ISRAEL): AN INTERIM ANALYSIS OF THE ROHS TRIAL by Nikitin, E., Dmitrieva, E., Morozov, D., Suvorova, A., Sveshnikova, J., Vyscub, G., Matveeva, I., Klitochenko, T., Shipaeva, A., Shirokova, M., Samoilova, O., Kaplanov, K., Konstantinova, T., Poddubnaya, I., Ptushkin, V.

“…Background: Autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) are well recognized autoimmune complications (AIC) of chronic lymphocytic…”
Get full text

PB2217 EPIDEMIOLOGICAL, CLINICAL, MOLECULAR AND GENETIC CHARACTERISTICS OF PRIMARY MYELOFIBROSIS IN THE RUSSIAN FEDERATION by Melikyan, A., Subortseva, I., Baryshniikova, D., Volodicheva, E., Gilyazitdinova, E., Glonina, N., Dimov, G., Ivanova, M., Kaplanov, K., Kaplina, A., Kirillova, E., Kiseleva, M., Klitochenko, T., Koloshejnova, T., Komarceva, E., Kulikov, S., Lomaia, E., Mihalev, M., Senderova, O., Fominykh, M., Hazieva, A., CHabaeva, Y., CHernyh, Y., Shashkina, K., SHuvaev, V.

“…Background: To date studies have not been conducted to assess the epidemiological characteristics of Ph‐negative myeloproliferative neoplasms, in particular…”
Get full text

Mutation status of refractory to imatinib patients with chronic myeloid leukemia by E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan

“…Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations…”
Get full text

Mutation status of refractory to imatinib patients with chronic myeloid leukemia by E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan

“…Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations…”
Get full text